 |
23 Diseases |  |
162 Trials |
|
162 Trials |  |
4758 News |  |
| «12...49505152535455565758596061» |
- Trial primary completion date, Combination therapy: ROMULUS: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov) - Nov 20, 2014
P2, N=124, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Sep 2017 --> Jun 2019
- ||| Copiktra (duvelisib) / Secura Bio, Yakult Honsha
New P1 trial, Combination therapy: Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) (clinicaltrials.gov) - Nov 17, 2014
P1, N=64, Not yet recruiting, Sponsor: Infinity Pharmaceuticals, Inc.
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
Enrollment open: A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Nov 12, 2014
P1, N=52, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2017 --> Jun 2019 Not yet recruiting --> Recruiting
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open, Combination therapy: GAUDI: A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 4, 2014
P1, N=136, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- |||||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open, Combination therapy: iLLUMINATE : A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na (clinicaltrials.gov) - Oct 22, 2014
P3, N=212, Recruiting, Sponsor: Pharmacyclics
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P3 trial, Combination therapy: iLLUMINATE : A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na (clinicaltrials.gov) - Oct 17, 2014
P3, N=212, Not yet recruiting, Sponsor: Pharmacyclics
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Combination therapy: A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) (clinicaltrials.gov) - Oct 17, 2014
P1/2, N=40, Recruiting, Sponsor: University of California, San Diego
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P2 trial, Combination therapy: GO29365: A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 10, 2014
P2, N=224, Recruiting, Sponsor: Hoffmann-La Roche
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P3 trial: CLL14 study: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 19, 2014
P3, N=432, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||||| Zydelig (idelalisib) / Gilead
Enrollment change, Trial initiation date, Trial primary completion date, Combination therapy: Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 11, 2014
P3, N=306, Not yet recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting N=176 --> 306 | Initiation date: Aug 2014 --> Jan 2015 | Trial primary completion date: Jun 2016 --> Dec 2018
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Combination therapy: A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) (clinicaltrials.gov) - Sep 4, 2014
P1/2, N=40, Not yet recruiting, Sponsor: University of California, San Diego
- ||| Gazyva (obinutuzumab) / Roche, Biogen
Clinical: Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
New P1 trial: A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Aug 21, 2014
P1, N=52, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date, Monotherapy: GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 19, 2014
P2, N=175, Completed, Sponsor: Hoffmann-La Roche
N=176 --> 306 | Initiation date: Aug 2014 --> Jan 2015 | Trial primary completion date: Jun 2016 --> Dec 2018 Trial primary completion date: Mar 2013 --> Sep 2011
- || Trial primary completion date, Combination therapy: ROMULUS: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov) - Aug 6, 2014
P2, N=124, Active, not recruiting, Sponsor: Genentech
Trial primary completion date: Mar 2013 --> Sep 2011 Trial primary completion date: Dec 2015 --> Sep 2017
- ||| Tecentriq (atezolizumab) / Roche
Enrollment open, Combination therapy, Metastases: A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 5, 2014
P1, N=200, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2015 --> Sep 2017 Not yet recruiting --> Recruiting
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Enrollment closed, Combination therapy: A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) (clinicaltrials.gov) - Aug 5, 2014
P3, N=1418, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease (clinicaltrials.gov) - Jul 30, 2014
P1, N=45, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Enrollment closed, Metastases: A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) (clinicaltrials.gov) - Jul 23, 2014
P3, N=1401, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Trial primary completion date, Combination therapy: Phase 1b Safety and Efficacy Study of TRU-016 (clinicaltrials.gov) - Jun 27, 2014
P1, N=68, Recruiting, Sponsor: Emergent Product Development Seattle LLC
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Jun 2015
- ||| Tecentriq (atezolizumab) / Roche
New P1 trial, Combination therapy, Metastases: A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 27, 2014
P1, N=200, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||| Enrollment open, Combination therapy: Phase 1b Safety and Efficacy Study of TRU-016 (clinicaltrials.gov) - Jun 27, 2014
P1, N=68, Recruiting, Sponsor: Emergent Product Development Seattle LLC
Trial primary completion date: Sep 2014 --> Jun 2015 Active, not recruiting --> Recruiting
- ||| Enrollment open, Enrollment change, Trial primary completion date, Combination therapy: Phase 1b Safety and Efficacy Study of TRU-016 (clinicaltrials.gov) - Jun 24, 2014
P1, N=56, Active, not recruiting, Sponsor: Emergent Product Development Seattle LLC
Active, not recruiting --> Recruiting N=24 --> 56 | Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2014 --> Jun 2015
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial primary completion date: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma (clinicaltrials.gov) - Jun 3, 2014
P1/2, N=200, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
N=24 --> 56 | Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2014 --> Jun 2015 Trial primary completion date: Jun 2014 --> Apr 2019
- ||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open, Combination therapy: CAVALLI: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL (clinicaltrials.gov) - May 25, 2014
P1, N=248, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2014 --> Apr 2019 Not yet recruiting --> Recruiting
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial primary completion date: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 20, 2014
P1/2, N=72, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2018 --> May 2018
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial initiation date: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 20, 2014
P1/2, N=72, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2018 --> May 2018 Initiation date: Jun 2014 --> May 2014
- |||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 20, 2014
P1/2, N=72, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Jun 2014 --> May 2014 Not yet recruiting --> Recruiting
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial initiation date: A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Apr 27, 2014
P2, N=72, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Initiation date: Mar 2014 --> Apr 2014
- |||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Mar 30, 2014
P2, N=72, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- | Ukoniq (umbralisib) / TG Therap
New P1 trial, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Mar 30, 2014
P1, N=30, Recruiting, Sponsor: TG Therapeutics, Inc.
- |||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Enrollment open, Metastases: A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) (clinicaltrials.gov) - Mar 30, 2014
P3, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- || Enrollment closed, Combination therapy: Phase 1b Safety and Efficacy Study of TRU-016 (clinicaltrials.gov) - Feb 24, 2014
P1, N=56, Active, not recruiting, Sponsor: Emergent Product Development Seattle LLC
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P2 trial: A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Feb 23, 2014
P2, N=72, Recruiting, Sponsor: Hoffmann-La Roche
- || Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial initiation date, Combination therapy: A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Feb 16, 2014
P1, N=70, Recruiting, Sponsor: Genentech
Recruiting --> Active, not recruiting Initiation date: Dec 2012 --> Jan 2014
- ||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P1 trial, Combination therapy: CAVALLI: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL (clinicaltrials.gov) - Feb 3, 2014
P1, N=248, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
New P3 trial: CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) (clinicaltrials.gov) - Feb 1, 2014
P3, N=787, Active, not recruiting, Sponsor: Hoffmann-La Roche
- ||| Enrollment closed, Combination therapy: ROMULUS: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (clinicaltrials.gov) - Jan 26, 2014
P2, N=124, Active, not recruiting, Sponsor: Genentech
Initiation date: Dec 2012 --> Jan 2014 Recruiting --> Active, not recruiting
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
New P3 trial: CLL11: A Study of RO5072759 (GA101) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 12, 2014
P3, N=787, Active, not recruiting, Sponsor: Hoffmann-La Roche
- |||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion, Monotherapy: A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN) (clinicaltrials.gov) - Jan 12, 2014
P2, N=134, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Trial initiation date: Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 15, 2013
P2, N=150, Recruiting, Sponsor: PrECOG, LLC.
Active, not recruiting --> Completed Initiation date: Aug 2013 --> Dec 2013
- |||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open: Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 15, 2013
P2, N=150, Recruiting, Sponsor: PrECOG, LLC.
Initiation date: Aug 2013 --> Dec 2013 Not yet recruiting --> Recruiting
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
New P3 trial: CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) (clinicaltrials.gov) - Nov 28, 2013
P3, N=787, Active, not recruiting, Sponsor: Hoffmann-La Roche
- |||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Nov 25, 2013
P3, N=800, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P1/2 trial: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 24, 2013
P1/2, N=72, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open, Combination therapy: A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 24, 2013
P1, N=90, Recruiting, Sponsor: Genentech
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) (clinicaltrials.gov) - Nov 24, 2013
P3, N=787, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- ||| Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P1 trial, Combination therapy: A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 21, 2013
P1, N=90, Recruiting, Sponsor: Genentech
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed, Combination therapy: GAUDI: A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 12, 2013
P1, N=137, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Zydelig (idelalisib) / Gilead
New P3 trial, Combination therapy: Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Nov 7, 2013
P3, N=176, Not yet recruiting, Sponsor: Gilead Sciences